ChromaDex Company

ChromaDex has developed a proprietary form of nicotinamide riboside (NR), a metabolic precursor of NAD+, which is a critical part of cellular functioning that declines with age. The company has conducted human clinical trials of its compound, showing that it increases NAD+ levels in humans, and it has been found to be safe by the FDA.
Technology: Cancer
Industry: Longevity
Headquarters: United States
Founded Date: 1999
Employees Number: 101-250
Funding Status: IPO
Estimated Revenue: $10M to $50M

Visit Website
Register and Claim Ownership